KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Receivables (2016 - 2025)

Idexx Laboratories has reported Receivables over the past 17 years, most recently at $865.1 million for Q4 2025.

  • Quarterly results put Receivables at $865.1 million for Q4 2025, up 20.17% from a year ago — trailing twelve months through Dec 2025 was $865.1 million (up 20.17% YoY), and the annual figure for FY2025 was $865.1 million, up 20.17%.
  • Receivables for Q4 2025 was $865.1 million at Idexx Laboratories, up from $855.6 million in the prior quarter.
  • Over the last five years, Receivables for IDXX hit a ceiling of $865.1 million in Q4 2025 and a floor of $504.4 million in Q1 2021.
  • Median Receivables over the past 5 years was $666.3 million (2023), compared with a mean of $669.2 million.
  • Biggest five-year swings in Receivables: surged 30.04% in 2021 and later grew 5.78% in 2024.
  • Idexx Laboratories' Receivables stood at $528.2 million in 2021, then grew by 11.96% to $591.4 million in 2022, then grew by 15.07% to $680.5 million in 2023, then grew by 5.78% to $719.9 million in 2024, then grew by 20.17% to $865.1 million in 2025.
  • The last three reported values for Receivables were $865.1 million (Q4 2025), $855.6 million (Q3 2025), and $835.4 million (Q2 2025) per Business Quant data.